Prana Biotechnology Ltd. (PRAN) Gains Key Patent for Alzheimer Compound
Prana Biotechnology Ltd., an Australian company established to commercialize research into Alzheimer’s Disease and other major age-related neurogenerative disorders, today announced that it has secured a key patent protecting its clinical drug (PBT2) with the European Patent Office. The patent covers the composition of matter of selected families of 8-Hydroxyquinoline compounds, including PBT2, and the uses of such compounds for the treatment of neurological diseases, such as Alzheimer’s Disease and Huntington’s Disease. PBT2, the company’s lead Alzheimer's Disease compound, has already demonstrated safety and tolerability in early Alzheimer's Disease patients in a Phase IIa study. It has also shown improvement…